Compare Stryker Corporation (SYK) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Teladoc Health Inc — how do they compare? Stryker Corporation trades at $346.82 (market cap $133.54B), while Teladoc Health Inc trades at $6.67 (market cap $1.24B). The key difference: Stryker Corporation is far larger — about 107.7× Teladoc Health Inc's market cap, and Stryker Corporation pays a 1.01% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| SYK | TDOC | |
|---|---|---|
Market Cap | $133.54B | $1.24B |
Sector | Technology | Health |
52-Week High | $394.34 | $9.72 |
52-Week Low | $282.58 | $4.47 |
Enterprise Value | $145.01B | $1.50B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $347.21, up 0.4% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, including a 9% organic sales growth in Q2 2026 and a net income margin of 14.43%. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS, expanding its robotic surgery portfolio. Analyst consensus is overwhelmingly positive, with 74% recommending Buy and a price target of $379.44.
The outlook for SYK is favorable, driven by robust earnings growth and strategic product launches. Key risks include cybersecurity vulnerabilities and margin pressures from tariffs. With no sell ratings and strong institutional support, the stock presents a compelling opportunity for growth-oriented investors, though monitoring quarterly execution remains critical.
Teladoc Health (TDOC) trades at $6.62, down 6.5% on the day, reflecting investor concern after a Q2 2026 revenue miss and lowered full-year guidance. The stock is technically bearish with key support at $6, while fundamentals show revenue of $2.53B in 2025 but persistent net losses, with a negative net income margin of -7.13%. Recent news highlights multiple law firm investigations into the company following its guidance cut.
The outlook remains challenging due to weak BetterHelp performance and ongoing losses, though valuation ratios like P/S of 0.49 and EV/EBITDA of 6.96 suggest potential undervaluation. Risks include competitive pressures and legal scrutiny, but analyst consensus price target of $8.88 implies upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
